Medulloblastoma, an invasive form of cancer of the brain. Credit: ASCOcancer
Medulloblastoma, an invasive form of cancer of the brain. Credit: ASCOcancer A new study shows the urgency of tailoring treatment regimens based on several criteria to provide better health outcomes for medulloblastoma patients. Hallie Coltin, pediatric hemato-oncologist and researcher at CHU Sainte-Justine and clinical assistant professor at the Faculty of Medicine of the Université de Montréal. Credit: Charline Provost CHU Sainte-Justine From neurological problems to hearing loss and infertility, survivors of medulloblastoma, an aggressive form of brain cancer, are left with severe physical and cognitive impairments and have an overall mortality rate 21 times higher than the general population. These findings are from a new study led by Dr. Hallie Coltin , a pediatric hematologist/oncologist and researcher at CHU Sainte-Justine and assistant clinical professor at Université de Montréal's Faculty of Medicine. Published in late January in the Journal of Clinical Oncology along with an editorial , these results highlight the urgent need to tailor treatment regimens based on age, disease severity, and tumor biology to improve health outcomes. Medulloblastoma is the most common form of brain cancer in young people.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
